Real world use of carfilzomib therapy among patients with existing cardiovascular medical history

Prof Xavier Leleu speaks to ecancer at the 2019 International Myeloma Workshop meeting in Boston about the real-world use of carfilzomib therapy among patients with existing cardiovascular medical history.

He explains that most of the clinical trials for carfilzomib have excluded patients with prior issues of cardiovascular issues leaving this population with no data.

Prof Leleu reports that this study was able to show that patients with cardiovascular issues who have been exposed to carfilzomib experienced no major issues.

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php
+